

Bloodâ€™Brain Barrier Dysfunction as a Cause and Cons

Journal of Cerebral Blood Flow and Metabolism

33, 1500-1513

DOI: [10.1038/jcbfm.2013.135](https://doi.org/10.1038/jcbfm.2013.135)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mevalonate Kinase Deficiency and Neuroinflammation: Balance between Apoptosis and Pyroptosis. <i>International Journal of Molecular Sciences</i> , 2013, 14, 23274-23288.	1.8	32
2	Drug Delivery Across the Blood-Brain Barrier with Focused Ultrasound and Microbubbles. <i>Topics in Medicinal Chemistry</i> , 2013, , 143-158.	0.4	2
3	Interleukin-1 $\beta$ Induces Blood-Brain Barrier Disruption by Downregulating Sonic Hedgehog in Astrocytes. <i>PLoS ONE</i> , 2014, 9, e110024.	1.1	206
4	The Role of the Blood-Brain Barrier in the Pathogenesis of Senile Plaques in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2014, 2014, 1-7.	1.1	43
5	Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid- $\beta$ brain balance and the putative role of PPARs. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 176.	1.7	46
6	De-regulation of gene expression and alternative splicing affects distinct cellular pathways in the aging hippocampus. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 373.	1.8	101
7	Evolution of microRNA (miRNA) Structure and Function in Plants and Animals: Relevance to Aging and Disease. <i>Journal of Aging Science</i> , 2014, 02, .	0.5	14
8	Compounds Blocking Methylglyoxal-induced Protein Modification and Brain Endothelial Injury. <i>Archives of Medical Research</i> , 2014, 45, 753-764.	1.5	29
9	Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System. <i>Frontiers in Endocrinology</i> , 2014, 5, 142.	1.5	28
10	Role of the Blood-Brain Barrier in the Nutrition of the Central Nervous System. <i>Archives of Medical Research</i> , 2014, 45, 610-638.	1.5	137
11	Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. <i>Journal of Neurochemistry</i> , 2014, 129, 559-572.	2.1	155
12	A role for human brain pericytes in neuroinflammation. <i>Journal of Neuroinflammation</i> , 2014, 11, 104.	3.1	125
13	Role of cholesterol metabolism in the pathogenesis of Alzheimer's disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2014, 17, 319-323.	1.3	38
14	Involvement of the blood-brain barrier opening in cognitive decline in aged rats following orthopedic surgery and high concentration of sevoflurane inhalation. <i>Brain Research</i> , 2014, 1551, 13-24.	1.1	73
15	Regulation of Neurotropic Signaling by the Inducible, NF- $\kappa$ B-Sensitive miRNA-125b in Alzheimer's Disease (AD) and in Primary Human Neuronal-Glial (HNG) Cells. <i>Molecular Neurobiology</i> , 2014, 50, 97-106.	1.9	89
16	TREK-King the Blood-Brain-Barrier. <i>Journal of NeuroImmune Pharmacology</i> , 2014, 9, 293-301.	2.1	41
17	The role of amyloid-beta in the regulation of memory. <i>Biochemical Pharmacology</i> , 2014, 88, 479-485.	2.0	105
18	Can sleep apnea cause Alzheimer's disease?. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 47, 656-669.	2.9	78

#	ARTICLE	IF	CITATIONS
19	Pharmacogenomics of Alzheimer's Disease: Novel Therapeutic Strategies for Drug Development. <i>Methods in Molecular Biology</i> , 2014, 1175, 323-556.	0.4	60
20	Alpha synuclein is transported into and out of the brain by the blood-brain barrier. <i>Peptides</i> , 2014, 62, 197-202.	1.2	138
21	New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1221-1224.	2.8	26
22	Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier. <i>Trends in Neurosciences</i> , 2014, 37, 325-333.	4.2	49
23	MicroRNA (miRNA): Sequence and stability, viroid-like properties, and disease association in the CNS. <i>Brain Research</i> , 2014, 1584, 73-79.	1.1	36
24	Chronic Functional Bowel Syndrome Enhances Gut-Brain Axis Dysfunction, Neuroinflammation, Cognitive Impairment, and Vulnerability to Dementia. <i>Neurochemical Research</i> , 2014, 39, 624-644.	1.6	104
25	The impact of microglial activation on blood-brain barrier in brain diseases. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 362.	1.8	408
26	The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 295-302.	1.2	64
27	The dynamic blood-brain barrier. <i>FEBS Journal</i> , 2015, 282, 4067-4079.	2.2	433
28	Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 175-188.	1.2	34
29	Different Populations of Human Locus Ceruleus Neurons Contain Heavy Metals or Hyperphosphorylated Tau: Implications for Amyloid- $\beta$ and Tau Pathology in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 437-447.	1.2	37
30	Control of Inflammatory Responses: a New Paradigm for the Treatment of Chronic Neuronal Diseases. <i>Experimental Neurobiology</i> , 2015, 24, 95-102.	0.7	35
31	Facilitation of Drug Transport across the Blood-Brain Barrier with Ultrasound and Microbubbles. <i>Pharmaceutics</i> , 2015, 7, 275-293.	2.0	61
32	Can insulin signaling pathways be targeted to transport A $\beta$ out of the brain?. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 114.	1.7	27
33	Real-time estimation of paracellular permeability of cerebral endothelial cells by capacitance sensor array. <i>Scientific Reports</i> , 2015, 5, 11014.	1.6	9
34	Blood-Brain Barrier Damage and Dysfunction by Chemical Toxicity. , 2015, , 725-739.		2
35	Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. <i>Proteomics - Clinical Applications</i> , 2015, 9, 715-731.	0.8	113
36	Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases. <i>Neurodegenerative Diseases</i> , 2015, 15, 63-69.	0.8	89

#	ARTICLE	IF	CITATIONS
37	Nanotherapeutic strategies for the treatment of Alzheimer's disease. <i>Therapeutic Delivery</i> , 2015, 6, 177-195.	1.2	12
38	Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz. <i>Molecular Pharmacology</i> , 2015, 88, 304-315.	1.0	33
39	Sleep fragmentation and sepsis differentially impact blood-brain barrier integrity and transport of tumor necrosis factor- $\alpha$ in aging. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 259-265.	2.0	26
40	Clearance systems in the brain—implications for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015, 11, 457-470.	4.9	1,127
41	Structural brain alterations in heart failure: a review of the literature and implications for risk of Alzheimer's disease. <i>Heart Failure Reviews</i> , 2015, 20, 561-571.	1.7	50
42	HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 37.	3.0	114
43	Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2015, 3, 8.	2.4	127
44	Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies. <i>Neuron</i> , 2015, 88, 289-297.	3.8	164
45	Myeloid Cells in Alzheimer's Disease: Culprits, Victims or Innocent Bystanders?. <i>Trends in Neurosciences</i> , 2015, 38, 659-668.	4.2	60
46	Microbiota and the control of blood-tissue barriers. <i>Tissue Barriers</i> , 2015, 3, e1039691.	1.6	69
47	Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. <i>Journal of Experimental Medicine</i> , 2015, 212, 1529-1549.	4.2	65
48	Amyloid $\beta$ Oligomers Disrupt Blood-CSF Barrier Integrity by Activating Matrix Metalloproteinases. <i>Journal of Neuroscience</i> , 2015, 35, 12766-12778.	1.7	140
49	The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease. <i>Histochemistry and Cell Biology</i> , 2015, 144, 293-308.	0.8	19
50	Reliable disease biomarkers characterizing and identifying electrohypersensitivity and multiple chemical sensitivity as two etiopathogenic aspects of a unique pathological disorder. <i>Reviews on Environmental Health</i> , 2015, 30, 251-71.	1.1	59
51	Blood-brain barrier impairment in dementia: Current and future in vivo assessments. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 49, 71-81.	2.9	51
52	Cognitive Impairment in Multiple Sclerosis: Clinical, Radiologic and Pathologic Insights. <i>Brain Pathology</i> , 2015, 25, 79-98.	2.1	151
53	The blood-brain barrier in neuroimmunology: Tales of separation and assimilation. <i>Brain, Behavior, and Immunity</i> , 2015, 44, 1-8.	2.0	201
54	ADAMTS4, 5, 9, and 15 Expressions in the Autopsied Brain of Patients with Alzheimer's Disease: A Preliminary Immunohistochemistry Study. <i>Journal of Microbiology and Biotechnology</i> , 2016, 26, 7-14.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model. <i>Current Alzheimer Research</i> , 2016, 13, 663-677.	0.7	13
56	Searching the Linkage between High Fat Diet and Alzheimer's Disease: A Debatable Proof Stand for Ketogenic Diet to Alleviate Symptoms of Alzheimer's Patient with APOE $\epsilon$ 4 Allele. <i>Journal of Neurology &amp; Neurophysiology</i> , 2016, 07, .	0.1	13
57	HIV-1 Tat Regulates Occludin and A $\beta$ Transfer Receptor Expression in Brain Endothelial Cells via Rho/ROCK Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	19
58	PD98059 Protects Brain against Cells Death Resulting from ROS/ERK Activation in a Cardiac Arrest Rat Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.	1.9	32
59	Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective. <i>Nutrients</i> , 2016, 8, 828.	1.7	22
60	In Vivo Amyloid- $\beta$ Imaging in the APPPS1 $\epsilon$ 21 Transgenic Mouse Model with a 89Zr-Labeled Monoclonal Antibody. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 67.	1.7	3
61	Restraint Stress-Induced Morphological Changes at the Blood-Brain Barrier in Adult Rats. <i>Frontiers in Molecular Neuroscience</i> , 2015, 8, 88.	1.4	84
62	The Rationale for Insulin Therapy in Alzheimer's Disease. <i>Molecules</i> , 2016, 21, 689.	1.7	14
63	Modulating Role of TTR in A $\beta$ Toxicity, from Health to Disease. , 0, , .		1
64	Distribution of human umbilical cord blood-derived mesenchymal stem cells in the Alzheimer's disease transgenic mouse after a single intravenous injection. <i>NeuroReport</i> , 2016, 27, 235-241.	0.6	33
65	Neuregulin1 $\epsilon$ 2 decreases interleukin1 $\alpha$ -induced RhoA activation, myosin light chain phosphorylation, and endothelial hyperpermeability. <i>Journal of Neurochemistry</i> , 2016, 136, 250-257.	2.1	11
66	Anti-Viral Properties of Amyloid- $\beta$ Peptides. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 859-878.	1.2	70
67	Monitoring Blood-Brain Barrier Integrity Following Amyloid- $\beta$ Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 723-735.	1.2	17
68	Glucose Transporters in Brain: In Health and in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1307-1320.	1.2	160
69	Sleep deprivation. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 583-588.	1.2	21
70	Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 445-456.	1.2	45
71	Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. <i>Journal of Controlled Release</i> , 2016, 235, 34-47.	4.8	1,018
72	Brain imaging of neurovascular dysfunction in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 131, 687-707.	3.9	160

#	ARTICLE	IF	CITATIONS
73	Nepriylsin Inhibition in the Time of Precision Medicine —. JACC: Heart Failure, 2016, 4, 409-414.	1.9	9
74	Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer's disease in T2DM patients. Endocrine, 2016, 53, 350-363.	1.1	65
75	Inhibitory effect of melatonin on cerebral endothelial cells dysfunction induced by methamphetamine via NADPH oxidase-2. Brain Research, 2016, 1650, 84-92.	1.1	12
76	Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. Journal of Molecular Psychiatry, 2016, 4, 3.	2.0	28
77	Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?. Neuron, 2016, 91, 957-973.	3.8	123
78	Systemic and localized extra-central nervous system bacterial infections and the risk of dementia among US veterans: A retrospective cohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 109-117.	1.2	20
79	Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. Journal of Controlled Release, 2016, 243, 1-10.	4.8	90
80	Alzheimer Mythology: A Time to Think Out of the Box. Journal of the American Medical Directors Association, 2016, 17, 769-774.	1.2	15
81	Alzheimer's disease: are blood and brain markers related? A systematic review. Annals of Clinical and Translational Neurology, 2016, 3, 455-462.	1.7	14
82	Characterizing blood-brain barrier perturbations after exposure to human triglyceride-rich lipoprotein lipolysis products using MRI in a rat model. Magnetic Resonance in Medicine, 2016, 76, 1246-1251.	1.9	8
83	Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. Experimental Biology and Medicine, 2016, 241, 1676-1683.	1.1	34
84	Cerebral vasomotor reactivity in neurodegenerative diseases. Neurologia I Neurochirurgia Polska, 2016, 50, 455-462.	0.6	29
85	Tau Proteins Cross the Blood-Brain Barrier. Journal of Alzheimer's Disease, 2016, 55, 411-419.	1.2	50
86	Pharmacogenomics of Antidepressant Drugs. , 2016, , 545-609.		2
87	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	0.8	21
88	Inhibition of ADAM10 promotes the clearance of A $\beta$ across the BBB by reducing LRP1 ectodomain shedding. Fluids and Barriers of the CNS, 2016, 13, 14.	2.4	31
89	Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?. Medicine (United States), 2016, 95, e4206.	0.4	18
90	Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. Radiology, 2016, 281, 527-535.	3.6	411

#	ARTICLE	IF	CITATIONS
91	The role of the low-density lipoprotein receptor-related protein 1 (LRP-1) in regulating blood-brain barrier integrity. <i>Reviews in the Neurosciences</i> , 2016, 27, 623-634.	1.4	55
92	Optimal acquisition and modeling parameters for accurate assessment of low $K_{trans}$ blood-brain barrier permeability using dynamic contrast-enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 1967-1977.	1.9	87
93	From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 275-292.	21.5	778
94	Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 409-425.	2.5	79
95	Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting $A\beta^2$ amyloid aggregates. <i>Journal of Biological Inorganic Chemistry</i> , 2016, 21, 83-99.	1.1	19
96	Valsartan/Sacubitril for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 25.	3.8	38
97	The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease. <i>Journal of Nutritional Biochemistry</i> , 2016, 38, 1-11.	1.9	91
98	Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cells. <i>Methods</i> , 2016, 101, 93-102.	1.9	123
99	Extracellular vesicles of the blood-brain barrier. <i>Tissue Barriers</i> , 2016, 4, e1131804.	1.6	77
100	Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 3793-3811.	1.9	48
101	The blood-brain barrier in systemic inflammation. <i>Brain, Behavior, and Immunity</i> , 2017, 60, 1-12.	2.0	714
102	Asymmetric Amyloid Deposition in the Brain Following Unilateral Electroconvulsive Therapy. <i>Biological Psychiatry</i> , 2017, 81, e11-e13.	0.7	4
103	Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer's disease. <i>Acta Neurologica Belgica</i> , 2017, 117, 229-234.	0.5	16
105	Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. <i>Human Antibodies</i> , 2017, 25, 131-146.	0.6	14
106	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	1.3	78
107	Vascular protective effects of KLF2 on $A\beta^2$ -induced toxicity: Implications for Alzheimer's disease. <i>Brain Research</i> , 2017, 1663, 174-183.	1.1	16
108	Early neurovascular dysfunction in a transgenic rat model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 46427.	1.6	83
109	Determination of Evans blue as a blood-brain barrier integrity tracer in plasma and brain tissue by UHPLC/UV method. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2017, 40, 442-448.	0.5	6

#	ARTICLE	IF	CITATIONS
110	Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. <i>Acta Neuropathologica</i> , 2017, 134, 207-220.	3.9	90
111	Characterisation of extracellular vesicle subsets derived from brain endothelial cells and analysis of their protein cargo modulation after TNF exposure. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1302705.	5.5	96
112	Subtle blood-brain barrier leakage rate and spatial extent: Considerations for dynamic contrast-enhanced MRI. <i>Medical Physics</i> , 2017, 44, 4112-4125.	1.6	75
113	Pathophysiology of the Blood-Brain Barrier in Neuroinflammatory Diseases. , 2017, , 61-79.		0
114	The blood brain barrier in Alzheimer's disease. <i>Vascular Pharmacology</i> , 2017, 89, 12-18.	1.0	84
115	Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 262-273.	2.0	32
116	Different impacts of acylated and non-acylated long-acting insulin analogs on neural functions in vitro and in vivo. <i>Diabetes Research and Clinical Practice</i> , 2017, 129, 62-72.	1.1	12
117	Neuroimaging and its Relevance to Understanding Pathways Linking Diabetes and Cognitive Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 405-419.	1.2	41
118	Brain barriers in health and disease. <i>Neurobiology of Disease</i> , 2017, 107, 1-3.	2.1	34
119	Stem cell models of Alzheimer's disease: progress and challenges. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 42.	3.0	112
121	Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. <i>Physiology</i> , 2017, 32, 20-32.	1.6	38
122	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017, 51, 104-112.	1.5	154
123	A 3D neurovascular microfluidic model consisting of neurons, astrocytes and cerebral endothelial cells as a blood-brain barrier. <i>Lab on A Chip</i> , 2017, 17, 448-459.	3.1	338
124	Kynurenine Pathway Metabolites in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 495-504.	1.2	99
125	Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease. <i>Pharmaceutical Research</i> , 2017, 34, 2652-2662.	1.7	11
126	Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia. <i>Stroke</i> , 2017, 48, 2799-2804.	1.0	85
127	Metabolite Clearance During Wakefulness and Sleep. <i>Handbook of Experimental Pharmacology</i> , 2017, 253, 385-423.	0.9	23
128	<i>Crocus sativus</i> Extract Tightens the Blood-Brain Barrier, Reduces Amyloid $\beta^2$ Load and Related Toxicity in 5XFAD Mice. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1756-1766.	1.7	66



#	ARTICLE	IF	CITATIONS
129	Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access. <i>AAPS Journal</i> , 2017, 19, 940-956.	2.2	16
130	NIH workshop report on the trans-agency blood-brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 12.	2.4	16
131	SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. <i>AAPS Journal</i> , 2017, 19, 1317-1331.	2.2	104
132	Conformational Change of Mutant form of Amyloid Precursor Protein by Carbon Nanotube Functionalized with Morin. <i>Nano LIFE</i> , 2017, 07, 1750001.	0.6	0
133	Aging of cerebral white matter. <i>Ageing Research Reviews</i> , 2017, 34, 64-76.	5.0	191
134	Inflammation at the blood-brain barrier: The role of liver X receptors. <i>Neurobiology of Disease</i> , 2017, 107, 57-65.	2.1	20
135	The blood-brain barrier in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2017, 107, 41-56.	2.1	454
136	Making a Bad Diagnosis Worse? Suspect Drug Management of Urinary Incontinence in Persons with Dementia. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 238-240.	1.3	0
137	Annexin A1 restores $\text{H}_2\text{O}_2$ -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. <i>Ageing Cell</i> , 2017, 16, 149-161.	3.0	87
138	Pathogenic Angiogenic Mechanisms in Alzheimer's Disease. , 0, , .		3
139	Maintenance of Blood-Brain Barrier Integrity in Hypertension: A Novel Benefit of Exercise Training for Autonomic Control. <i>Frontiers in Physiology</i> , 2017, 8, 1048.	1.3	51
140	Multifunctional Effects of Human Serum Albumin Toward Neuroprotection in Alzheimer's Disease. , 2017, , 217-238.		4
141	Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1965.	1.8	273
142	Novel Treatment Strategies Using TiO <sub>2</sub> -Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease. <i>International Review of Neurobiology</i> , 2017, 137, 123-165.	0.9	23
143	Age Drives Distortion of Brain Metabolic, Vascular and Cognitive Functions, and the Gut Microbiome. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 298.	1.7	96
144	Seeking a New Paradigm for Alzheimer's Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease. <i>International Journal of Alzheimer's Disease</i> , 2017, 2017, 1-6.	1.1	4
145	Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration. <i>BioMed Research International</i> , 2017, 2017, 1-14.	0.9	3
146	Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?. <i>BMC Neurology</i> , 2017, 17, 163.	0.8	5

#	ARTICLE	IF	CITATIONS
147	The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets. <i>Translational Neurodegeneration</i> , 2017, 6, 22.	3.6	39
148	Alzheimer's Disease as the Product of a Progressive Energy Deficiency Syndrome in the Central Nervous System: The Neuroenergetic Hypothesis. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1223-1229.	1.2	32
149	Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity. <i>Cell Death and Disease</i> , 2017, 8, e3102-e3102.	2.7	46
150	Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 6, 465-476.	0.6	6
151	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. <i>Neuropharmacology</i> , 2018, 136, 223-242.	2.0	38
152	Catalpol provides a protective effect on fibrillary A $\beta$ <sub>1-42</sub> -induced barrier disruption in an in vitro model of the blood-brain barrier. <i>Phytotherapy Research</i> , 2018, 32, 1047-1055.	2.8	23
153	Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. <i>Pharmacological Reviews</i> , 2018, 70, 278-314.	7.1	242
154	Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. <i>Journal of Neurochemistry</i> , 2018, 146, 670-685.	2.1	59
155	Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. <i>Brain</i> , 2018, 141, 1637-1649.	3.7	49
156	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2018, 135, 62-74.	6.6	78
157	Bisphosphonates: Future perspective for neurological disorders. <i>Pharmacological Reports</i> , 2018, 70, 900-907.	1.5	35
158	Neuroprotective effects of silk fibroin hydrolysate against A $\beta$ <sub>25-35</sub> induced cytotoxicity in SH-SY5Y cells and primary hippocampal neurons by regulating ROS inactivation of PP2A. <i>Journal of Functional Foods</i> , 2018, 45, 100-109.	1.6	13
159	Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy. <i>Neurotoxicity Research</i> , 2018, 34, 733-748.	1.3	137
160	Can Curcumin Counteract Cognitive Decline? Clinical Trial Evidence and Rationale for Combining $\omega$ -3 Fatty Acids with Curcumin. <i>Advances in Nutrition</i> , 2018, 9, 105-113.	2.9	20
161	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
162	A new model for chronic diseases. <i>Medical Hypotheses</i> , 2018, 113, 30-39.	0.8	4
163	Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 133-150.	4.9	1,731
164	Functional morphology of the blood-brain barrier in health and disease. <i>Acta Neuropathologica</i> , 2018, 135, 311-336.	3.9	543

#	ARTICLE	IF	CITATIONS
165	In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain. <i>Journal of Controlled Release</i> , 2018, 273, 108-130.	4.8	43
166	A Perfect sTORM: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review. <i>Gerontology</i> , 2018, 64, 205-211.	1.4	30
167	Transplantation of in vitro cultured endothelial progenitor cells repairs the blood-brain barrier and improves cognitive function of APP/PS1 transgenic AD mice. <i>Journal of the Neurological Sciences</i> , 2018, 387, 6-15.	0.3	23
168	Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. <i>Medicinal Research Reviews</i> , 2018, 38, 261-324.	5.0	55
169	ZO-1 expression is suppressed by GM-CSF via miR-96/ERG in brain microvascular endothelial cells. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 809-822.	2.4	26
170	A story of birth and death: Insights into the formation and dynamics of the microglial population. <i>Brain, Behavior, and Immunity</i> , 2018, 69, 9-17.	2.0	34
171	Activation of RAR $\alpha$ , RAR $\beta$ , or RXR $\alpha$ Increases Barrier Tightness in Human Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells. <i>Biotechnology Journal</i> , 2018, 13, 1700093.	1.8	39
172	Recent Advances in Computational Approaches for Designing Potential Anti-Alzheimer's Agents. <i>Neuromethods</i> , 2018, , 25-59.	0.2	3
173	Reduced glucose transporter-1 in brain derived circulating endothelial cells in mild Alzheimer's disease patients. <i>Brain Research</i> , 2018, 1678, 304-309.	1.1	20
174	Effects of donepezil on liver and kidney functions for the treatment of Alzheimer's disease. <i>Journal of Integrative Neuroscience</i> , 2018, 16, 335-346.	0.8	8
175	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. <i>Advanced Materials</i> , 2018, 30, e1801362.	11.1	415
176	Microorganisms' Footprint in Neurodegenerative Diseases. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 466.	1.8	42
177	Innate Immunity Cells and the Neurovascular Unit. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3856.	1.8	38
178	Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimer's Type Dementia. <i>Frontiers in Neuroscience</i> , 2018, 12, 851.	1.4	17
179	Isolation of Cerebral Capillaries from Fresh Human Brain Tissue. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	18
180	Brain Imaging in Type 2 Diabetes. , 2018, , 49-66.		0
181	Unravelling the glial response in the pathogenesis of Alzheimer's disease. <i>FASEB Journal</i> , 2018, 32, 5766-5777.	0.2	30
182	Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier. <i>Fluids and Barriers of the CNS</i> , 2018, 15, 30.	2.4	142

#	ARTICLE	IF	CITATIONS
183	Leaky Gut, Leaky Brain?. <i>Microorganisms</i> , 2018, 6, 107.	1.6	153
184	Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 284.	1.7	99
185	Changes in the Blood-Brain Barrier Function Are Associated With Hippocampal Neuron Death in a Kainic Acid Mouse Model of Epilepsy. <i>Frontiers in Neurology</i> , 2018, 9, 775.	1.1	25
186	Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier. , 0, . .		10
187	Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H693-H703.	1.5	89
188	Astrocytic degeneration in chronic traumatic encephalopathy. <i>Acta Neuropathologica</i> , 2018, 136, 955-972.	3.9	51
189	Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1283-1299.	1.2	22
190	Potential roles of brain barrier dysfunctions in the early stage of Alzheimer's disease. <i>Brain Research Bulletin</i> , 2018, 142, 360-367.	1.4	8
191	Cerebral small vessel disease and the risk of Alzheimer's disease: A systematic review. <i>Ageing Research Reviews</i> , 2018, 47, 41-48.	5.0	62
192	Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 421-431.	1.2	37
193	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 761-774.	1.2	7
194	Neuroinflammation in Age-Related Neurodegenerative Diseases. , 2018, , 477-507.		0
195	A novel dynamic multicellular co-culture system for studying individual blood-brain barrier cell types in brain diseases and cytotoxicity testing. <i>Scientific Reports</i> , 2018, 8, 8784.	1.6	31
196	Functional MRI of brain physiology in aging and neurodegenerative diseases. <i>NeuroImage</i> , 2019, 187, 209-225.	2.1	55
197	Microglia in the Neurovascular Unit: Blood-Brain Barrier-microglia Interactions After Central Nervous System Disorders. <i>Neuroscience</i> , 2019, 405, 55-67.	1.1	119
198	Mercury in the retina and optic nerve following prenatal exposure to mercury vapor. <i>PLoS ONE</i> , 2019, 14, e0220859.	1.1	22
199	Chronic Cerebral Hypoperfusion Activates the Coagulation and Complement Cascades in Alzheimer's Disease Mice. <i>Neuroscience</i> , 2019, 416, 126-136.	1.1	26
200	miR-424-5p maybe regulate blood-brain barrier permeability in a model in vitro with Abeta incubated endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 525-531.	1.0	15

#	ARTICLE	IF	CITATIONS
201	The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 20.	2.4	51
202	Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1 $\alpha$ /NRF1/TFAM. <i>IUBMB Life</i> , 2019, 71, 1515-1521.	1.5	22
203	The Blood-Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5472.	1.8	61
204	Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. <i>Critical Care</i> , 2019, 23, 352.	2.5	235
205	Inflammatory and Pro-resolving Mediators in Frontotemporal Dementia and Alzheimer's Disease. <i>Neuroscience</i> , 2019, 421, 123-135.	1.1	17
206	Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. <i>Biomaterials</i> , 2019, 224, 119491.	5.7	306
207	Norvaline Restores the BBB Integrity in a Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4616.	1.8	16
208	Blood-brain barrier at the interface of air pollution-associated neurotoxicity and neuroinflammation. <i>Advances in Neurotoxicology</i> , 2019, , 295-337.	0.7	3
209	Propofol improved hypoxia-impaired integrity of blood-brain barrier via modulating the expression and phosphorylation of zonula occludens-1. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 704-713.	1.9	31
210	Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation. <i>Frontiers in Neurology</i> , 2019, 9, 1158.	1.1	34
211	Royal Jelly Alleviates Cognitive Deficits and $\beta$ -Amyloid Accumulation in APP/PS1 Mouse Model Via Activation of the cAMP/PKA/CREB/BDNF Pathway and Inhibition of Neuronal Apoptosis. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 428.	1.7	45
212	Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology. <i>Molecular Neurobiology</i> , 2019, 56, 5815-5834.	1.9	38
213	Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and $\alpha$ -tocopherol. <i>Neurobiology of Disease</i> , 2019, 125, 123-134.	2.1	24
214	Sex differences in the expression of cell adhesion molecules on microvesicles derived from cultured human brain microvascular endothelial cells treated with inflammatory and thrombotic stimuli. <i>Biology of Sex Differences</i> , 2019, 10, 26.	1.8	16
215	Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1413-1432.	2.4	42
216	Effects of gold and PCL- or PLLA-coated silica nanoparticles on brain endothelial cells and the blood-brain barrier. <i>Beilstein Journal of Nanotechnology</i> , 2019, 10, 941-954.	1.5	12
217	Age-Associated Changes in the Immune System and Blood-Brain Barrier Functions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1632.	1.8	107
218	Immunoglobulin G transport increases in an in vitro blood-brain barrier model with amyloid $\beta$ and with neuroinflammatory cytokines. <i>Biotechnology and Bioengineering</i> , 2019, 116, 1752-1761.	1.7	16

#	ARTICLE	IF	CITATIONS
219	Bloodâ€“Brain Barrier. , 2019, , 325-336.		3
220	Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2019, 137, 801-823.	3.9	61
221	Blood-Brain Barrierâ€“Targeted Nanotechnological Advances. , 2019, , 25-31.		0
222	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. <i>Brain</i> , 2019, 142, 1077-1092.	3.7	120
223	Biomarkers of Bloodâ€“Brain Barrier Dysfunction. , 2019, , 997-1012.		3
224	Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (â€œchemobrainâ€), a condition that significantly impairs the quality of life of many cancer survivors. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1088-1097.	1.8	75
225	Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?. <i>Journal of Korean Medical Science</i> , 2019, 34, e297.	1.1	8
226	Plasma Extracellular Vesicles in Children with OSA Disrupt Bloodâ€“Brain Barrier Integrity and Endothelial Cell Wound Healing In Vitro. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6233.	1.8	18
227	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. <i>Antibodies</i> , 2019, 8, 56.	1.2	46
228	The leukotriene signaling pathway: a druggable target in Alzheimerâ€™s disease. <i>Drug Discovery Today</i> , 2019, 24, 505-516.	3.2	48
229	Current Perspectives and Mechanisms of Relationship between Intestinal Microbiota Dysfunction and Dementia: A Review. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 360-381.	0.6	11
230	Extravascular fibrinogen in the white matter of Alzheimerâ€™s disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimerâ€™s disease. <i>Brain Pathology</i> , 2019, 29, 414-424.	2.1	24
231	Novel therapeutic strategies for Alzheimer's disease: Implications from cell-based therapy and nanotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102149.	1.7	35
232	Microphysiological systems for recapitulating physiology and function of blood-brain barrier. <i>Biomaterials</i> , 2020, 232, 119732.	5.7	34
233	MicroRNA-126-3p/-5p Overexpression Attenuates Blood-Brain Barrier Disruption in a Mouse Model of Middle Cerebral Artery Occlusion. <i>Stroke</i> , 2020, 51, 619-627.	1.0	78
234	Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimerâ€™s disease. <i>Science Advances</i> , 2020, 6, .	4.7	56
235	Structure and function of the perivascular fluid compartment and vertebral venous plexus: Illuminating a novel theory on mechanisms underlying the pathogenesis of Alzheimer's, cerebral small vessel, and neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2020, 144, 105022.	2.1	9
236	The Interplay Between Beta-Amyloid 1â€“42 (A $\beta$ 1â€“42)-Induced Hippocampal Inflammatory Response, p-tau, Vascular Pathology, and Their Synergistic Contributions to Neuronal Death and Behavioral Deficits. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 522073.	1.4	26

#	ARTICLE	IF	CITATIONS
237	Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction. <i>Neuroscientist</i> , 2021, 27, 668-684.	2.6	18
238	Association of Vitamin D Receptor Polymorphisms with Amyloid- $\beta$ Transporters Expression and Risk of Mild Cognitive Impairment in a Chilean Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 82, 1-14.	1.2	6
239	Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease. <i>Heliyon</i> , 2020, 6, e04716.	1.4	4
240	Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease. <i>Frontiers in Neuroendocrinology</i> , 2020, 59, 100857.	2.5	50
241	Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 570045.	1.4	77
242	The blood-brain barrier in health and disease: Important unanswered questions. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	365
243	Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine. <i>Chinese Journal of Integrative Medicine</i> , 2020, , 1.	0.7	8
244	Cerebral Small Vessel Disease and Alzheimer's Disease: A Review. <i>Frontiers in Neurology</i> , 2020, 11, 927.	1.1	53
245	Klotho overexpression improves amyloid- $\beta$ clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease. <i>Aging Cell</i> , 2020, 19, e13239.	3.0	51
246	Site-specific opening of the blood-brain barrier by extracellular histones. <i>Journal of Neuroinflammation</i> , 2020, 17, 281.	3.1	19
247	Aerobic exercise increases sprouting angiogenesis in the male rat motor cortex. <i>Brain Structure and Function</i> , 2020, 225, 2301-2314.	1.2	6
248	Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells. <i>Circulation</i> , 2020, 142, 1848-1862.	1.6	157
249	Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer's disease using a proteomics approach. <i>International Journal of Neuroscience</i> , 2020, , 1-12.	0.8	4
250	Mechanobiology of the brain in ageing and Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 3851-3878.	1.2	61
251	Interactions between Amyloid- $\beta$ Proteins and Human Brain Pericytes: Implications for the Pathobiology of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1490.	1.0	26
252	Perindopril ameliorates experimental Alzheimer's disease progression: role of amyloid $\beta$ degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling. <i>Inflammopharmacology</i> , 2020, 28, 1343-1364.	1.9	18
253	Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. <i>IUBMB Life</i> , 2020, 72, 1843-1855.	1.5	40
254	DSC Brain Perfusion Using Advanced Deconvolution Models in the Diagnostic Work-Up of Dementia and Mild Cognitive Impairment: A Semiquantitative Comparison with HMPAO-SPECT-Brain Perfusion. <i>Journal of Clinical Medicine</i> , 2020, 9, 1800.	1.0	6

#	ARTICLE	IF	CITATIONS
255	Extracellular Vesicles miRNA Cargo for Microglia Polarization in Traumatic Brain Injury. <i>Biomolecules</i> , 2020, 10, 901.	1.8	32
256	Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. <i>Biomaterials Science</i> , 2020, 8, 4109-4128.	2.6	85
257	Blood-brain barrier damage and dysfunction by chemical toxicity. , 2020, , 811-827.		0
258	Uncertainty in Pharmacology. <i>Boston Studies in the Philosophy and History of Science</i> , 2020, , .	0.4	1
259	Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients. <i>Neurological Sciences</i> , 2020, 41, 1865-1872.	0.9	23
260	Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP43 pathology. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 458-477.	1.8	29
261	Chronic cerebral hypoperfusion: An undefined, relevant entity. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 8-12.	0.8	33
262	Neurovascular unit dysregulation, white matter disease, and executive dysfunction: the shared triad of vascular cognitive impairment and Alzheimer disease. <i>GeroScience</i> , 2020, 42, 445-465.	2.1	50
263	Fish oil protects the blood-brain barrier integrity in a mouse model of Alzheimer's disease. <i>Chinese Medicine</i> , 2020, 15, 29.	1.6	14
264	White matter alterations in Alzheimer's disease without concomitant pathologies. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 654-672.	1.8	24
265	Microglia alterations in neurodegenerative diseases and their modeling with human induced pluripotent stem cell and other platforms. <i>Progress in Neurobiology</i> , 2020, 190, 101805.	2.8	35
266	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. <i>Medicinal Research Reviews</i> , 2021, 41, 2689-2745.	5.0	26
267	Nanomedicines for Brain Drug Delivery. <i>Neuromethods</i> , 2021, , .	0.2	3
268	Distinct Uptake Kinetics of Alzheimer Disease Amyloid- $\beta$ 40 and 42 at the Blood-Brain Barrier Endothelium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 482-490.	1.3	13
269	Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. <i>Molecular Psychiatry</i> , 2021, 26, 1044-1059.	4.1	104
270	First record on mercury accumulation in mice brain living in active volcanic environments: a cytochemical approach. <i>Environmental Geochemistry and Health</i> , 2021, 43, 171-183.	1.8	7
271	Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12204.	1.2	22
272	Nano-carriers for brain disorders targeting the blood brain barrier (BBB) crossing strategies. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2021, 7, 213-221.	0.1	0



#	ARTICLE	IF	CITATIONS
273	Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration. <i>Molecular Neurobiology</i> , 2021, 58, 2379-2394.	1.9	38
274	Selenium at the Neural Barriers: A Review. <i>Frontiers in Neuroscience</i> , 2021, 15, 630016.	1.4	36
275	Noncontrast assessment of blood-brain barrier permeability to water: Shorter acquisition, test-retest reproducibility, and comparison with contrast-based method. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 143-156.	1.9	16
276	Time-Dependent Internalization of Polymer-Coated Silica Nanoparticles in Brain Endothelial Cells and Morphological and Functional Effects on the Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1657.	1.8	5
277	The Neurovascular Unit Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2022.	1.8	65
278	Healthy aging and the blood-brain barrier. <i>Nature Aging</i> , 2021, 1, 243-254.	5.3	116
279	Plasma amyloid $\beta$ levels in Alzheimer's disease and cognitively normal controls in Syrian population. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 19.	0.9	2
280	Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 653651.	1.4	30
281	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <i>Biomolecules</i> , 2021, 11, 600.	1.8	16
283	Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons. <i>ACS Omega</i> , 2021, 6, 13033-13056.	1.6	7
284	Nanomedicine against Alzheimer's and Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 1507-1545.	0.9	7
285	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	1.2	18
286	An engineered neurovascular unit for modeling neuroinflammation. <i>Biofabrication</i> , 2021, 13, 035039.	3.7	18
287	Possible effects of <i>Porphyromonas gingivalis</i> on the blood-brain barrier in Alzheimer's disease. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1367-1371.	2.0	10
288	Use of Zebrafish Genetic Models to Study Etiology of the Amyloid-Beta and Neurofibrillary Tangle Pathways in Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2022, 20, 524-539.	1.4	8
289	B Cells in Neuroinflammation: New Perspectives and Mechanistic Insights. <i>Cells</i> , 2021, 10, 1605.	1.8	25
290	Role of Neuron and Glia in Alzheimer's Disease and Associated Vascular Dysfunction. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 653334.	1.7	28
291	Blood-Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease. <i>Annals of Neurology</i> , 2021, 90, 227-238.	2.8	57

#	ARTICLE	IF	CITATIONS
292	Homocysteine and Age-Related Central Nervous System Diseases: Role of Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6259.	1.8	19
293	Effects of Lipotoxicity in Brain Microvascular Endothelial Cells During Sirt3 Deficiency-Potential Role in Comorbid Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 716616.	1.7	14
294	Amyloid- $\beta^2$ disrupts unitary calcium entry through endothelial NMDA receptors in mouse cerebral arteries. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, , 0271678X2110395.	2.4	11
295	Blood-Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. <i>Frontiers in Neuroscience</i> , 2021, 15, 688090.	1.4	108
296	Effects of early-life stress and sex on blood-brain barrier permeability and integrity in juvenile and adult rats. <i>Developmental Neurobiology</i> , 2021, 81, 861-876.	1.5	8
297	The Complexity of the Blood-Brain Barrier and the Concept of Age-Related Brain Targeting: Challenges and Potential of Novel Solid Lipid-Based Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 577-592.	1.6	16
298	Effects of apolipoprotein E isoform, sex, and diet on insulin BBB pharmacokinetics in mice. <i>Scientific Reports</i> , 2021, 11, 18636.	1.6	8
299	Blood-brain barrier models: Rationale for selection. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113859.	6.6	23
300	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. <i>Cells</i> , 2021, 10, 2581.	1.8	42
301	Neutrophil-specific deletion of Syk results in recruitment-independent stabilization of the barrier and a long-term improvement in cognitive function after traumatic injury to the developing brain. <i>Neurobiology of Disease</i> , 2021, 157, 105430.	2.1	4
302	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. <i>Ageing Research Reviews</i> , 2021, 71, 101451.	5.0	20
304	Cu, Fe, and Zn isotope ratios in murine Alzheimer's disease models suggest specific signatures of amyloidogenesis and tauopathy. <i>Journal of Biological Chemistry</i> , 2021, 296, 100292.	1.6	24
305	Vascular Dysfunction and Neurodegenerative Disease. , 2020, , 3-16.		2
306	Neurodegenerative Diseases: The Real Problem and Nanobiotechnological Solutions. , 2019, , 1-17.		3
307	Contributions of Drug Transporters to Blood-Brain Barriers. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1141, 407-466.	0.8	10
308	Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. <i>Acta Neuropathologica</i> , 2020, 139, 813-836.	3.9	113
309	Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies. <i>Open Biology</i> , 2020, 10, 200286.	1.5	19
311	Gut Microbiota and Disorders of the Central Nervous System. <i>Neuroscientist</i> , 2020, 26, 487-502.	2.6	20

#	ARTICLE	IF	CITATIONS
312	Low Dose Cranial Irradiation-Induced Cerebrovascular Damage Is Reversible in Mice. PLoS ONE, 2014, 9, e112397.	1.1	56
313	Sulfur-containing Secondary Metabolites as Neuroprotective Agents. Current Medicinal Chemistry, 2020, 27, 4421-4436.	1.2	21
314	Central nervous system diseases associated with blood brain barrier breakdown - A Comprehensive update of existing literatures. Journal of Neuroscience and Neurological Disorders, 2020, 4, 053-062.	0.1	2
315	Hyperoside protects the blood-brain barrier from neurotoxicity of amyloid beta 1 $\alpha$ 42. Neural Regeneration Research, 2018, 13, 1974.	1.6	24
316	Chronic exposure to low doses of ozone produces a state of oxidative stress and blood-brain barrier damage in the hippocampus of rat. Advances in Bioscience and Biotechnology (Print), 2013, 04, 24-29.	0.3	12
317	Comparison of Erythrocytes for Individual Indications of Metabolism Changes in Parkinson $\alpha$ and Alzheimer $\alpha$ Diseases. , 0, , .		1
318	The Blood $\alpha$ Brain Barrier: Much More Than a Selective Access to the Brain. Neurotoxicity Research, 2021, 39, 2154-2174.	1.3	12
319	Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapy for Alzheimer $\alpha$ Disease: Progress and Opportunity. Membranes, 2021, 11, 796.	1.4	11
320	The Effects of Virgin Coconut Oil on Prevention of Alzheimer $\alpha$ Disease. Jundishapur Journal of Natural Pharmaceutical Products, 2019, 14, .	0.3	1
321	Predicting Alzheimer's Disease Onset. European Journal of Medical and Health Sciences, 2019, 1, .	0.1	3
322	Involvement of Astrocytes in the Process of Metabolic Syndrome. , 0, , .		0
323	Affected albumin endocytosis as a new neurotoxicity mechanism of amyloid beta. AIMS Neuroscience, 2020, 7, 344-359.	1.0	1
324	Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer $\alpha$ Measurement. Boston Studies in the Philosophy and History of Science, 2020, , 289-318.	0.4	2
325	Vascular Component of Neuroinflammation in Experimental Alzheimer $\alpha$ Disease in Mice. Cell and Tissue Biology, 2020, 14, 256-262.	0.2	0
326	The Use of Peptide and Protein Vectors to Cross the Blood-Brain Barrier for the Delivery of Therapeutic Concentration of Biologics. Neuromethods, 2021, , 119-147.	0.2	1
327	An overview on therapeutics attenuating amyloid $\beta^2$ level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. American Journal of Translational Research (discontinued), 2016, 8, 246-69.	0.0	30
328	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model. Current Alzheimer Research, 2016, 13, 663-77.	0.7	4
329	Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. , 2019, 7, 547-558.		0

#	ARTICLE	IF	CITATIONS
330	Targeting gut dysbiosis as a means to enhance recovery from surgical brain injury. <i>Surgical Neurology International</i> , 2021, 12, 210.	0.2	0
331	Multiplexed Ion Beam Imaging: Insights into Pathobiology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 403-423.	9.6	16
332	Post-stroke dizziness of visual-vestibular cortices origin. <i>Journal of Neuroscience and Neurological Disorders</i> , 2020, 4, 075-078.	0.1	0
333	Targeting gut dysbiosis as a means to enhance recovery from surgical brain injury. , 2021, 12, 210.		0
334	Myotubularin-related protein protects against neuronal degeneration mediated by oxidative stress or infection. <i>Journal of Biological Chemistry</i> , 2022, , 101614.	1.6	4
335	The amyloid- $\beta$ 42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution. <i>Journal of Biological Chemistry</i> , 2022, 298, 101483.	1.6	1
336	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease. <i>Annals of Translational Medicine</i> , 2022, 10, 65-65.	0.7	5
337	Severe Gestational Low-Protein Intake Impacts Hippocampal Cellularity, Tau, and Amyloid- $\beta$ Levels, and Memory Performance in Male Adult Offspring: An Alzheimer-Simile Disease Model?. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 17-30.	1.2	5
338	Impact of intestinal disorders on central and peripheral nervous system diseases. <i>Neurobiology of Disease</i> , 2022, 165, 105627.	2.1	17
339	Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer's disease mice. <i>Neuroscience Letters</i> , 2022, 774, 136528.	1.0	8
340	Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings. <i>Biochemical Pharmacology</i> , 2022, 197, 114945.	2.0	19
342	Peripheral Neutrophils-Derived Matrix Metalloproteinase-9 Induces Postoperative Cognitive Dysfunction in Aged Mice. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 683295.	1.7	4
343	A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer's disease: mechanism and brain delivery. <i>Journal of Pharmaceutical Investigation</i> , 2022, 52, 195.	2.7	1
344	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 51-81.	1.2	14
345	Sex differences in the blood-brain barrier: Implications for mental health. <i>Frontiers in Neuroendocrinology</i> , 2022, 65, 100989.	2.5	31
346	Induction of Heme Oxygenase-1 by 15d-Prostaglandin J2 Mediated via a ROS-Dependent Sp1 and AP-1 Cascade Suppresses Lipopolysaccharide-Triggered Interleukin-6 Expression in Mouse Brain Microvascular Endothelial Cells. <i>Antioxidants</i> , 2022, 11, 719.	2.2	4
347	New Horizons' Cognitive Dysfunction Associated With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 929-942.	1.8	5
348	The Role of Heparin and Glycocalyx in Blood-Brain Barrier Dysfunction. <i>Frontiers in Immunology</i> , 2021, 12, 754141.	2.2	12

#	ARTICLE	IF	CITATIONS
355	Claudin-5 relieves cognitive decline in Alzheimer's disease mice through suppression of inhibitory GABAergic neurotransmission. <i>Aging</i> , 2022, 14, 3554-3568.	1.4	7
356	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease.. <i>Annals of Translational Medicine</i> , 2022, 10, 65.	0.7	0
357	Pathophysiological Mechanisms Underlying Idiopathic Normal Pressure Hydrocephalus: A Review of Recent Insights. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 866313.	1.7	9
358	Why electrohypersensitivity and related symptoms are caused by non-ionizing man-made electromagnetic fields: An overview and medical assessment. <i>Environmental Research</i> , 2022, 212, 113374.	3.7	10
359	A multi-hit hypothesis for an APOE4-dependent pathophysiological state. <i>European Journal of Neuroscience</i> , 2022, 56, 5476-5515.	1.2	8
360	A novel strategy for delivering Nip2 proteins across the blood-brain barrier using the brain endothelial-specific AAV-BR1 virus. <i>Journal of Neurochemistry</i> , 2023, 164, 6-28.	2.1	4
361	Does Neuroinflammation Underlie the Cognitive Changes Observed With Dietary Interventions?. <i>Frontiers in Neuroscience</i> , 2022, 16, .	1.4	2
362	Blood-brain barrier permeability following conventional photon radiotherapy – A systematic review and meta-analysis of clinical and preclinical studies. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 44-55.	0.9	12
363	Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer's disease model. <i>Neurobiology of Disease</i> , 2022, 169, 105741.	2.1	14
364	Astrocytic Calcium and cAMP in Neurodegenerative Diseases. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, .	1.8	11
365	Shared pathophysiology: Understanding stroke and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2022, 218, 107306.	0.6	9
367	Blood-brain barrier permeability in response to caffeine challenge. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 2259-2266.	1.9	8
368	Fiscalin Derivatives as Potential Neuroprotective Agents. <i>Pharmaceutics</i> , 2022, 14, 1456.	2.0	3
369	Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease. <i>Neurochemical Research</i> , 2022, 47, 2954-2962.	1.6	14
370	Activation of Wnt/ $\beta$ -catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer's disease. <i>Brain</i> , 2022, 145, 4474-4488.	3.7	41
372	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	16
373	Perspectives on the Molecular Mediators of Oxidative Stress and Antioxidant Strategies in the Context of Neuroprotection and Neurolongevity: An Extensive Review. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	11
374	Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	4

#	ARTICLE	IF	CITATIONS
375	The emerging role of furin in neurodegenerative and neuropsychiatric diseases. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	19
376	The effect of chronic stress and its preconditioning on spatial memory as well as hippocampal LRP1 and RAGE expression in a streptozotocin-induced rat model of Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2022, 37, 2699-2710.	1.4	1
377	The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10136.	1.8	6
378	The role of LRP1 in A $\beta$ efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus. <i>Neurochemistry International</i> , 2022, 160, 105417.	1.9	2
379	Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer's Disease. , 2022, 13, 1391.		4
381	Advances in the study of the relationship between Alzheimer's disease and the gastrointestinal microbiome. , 2022, 8, 465-475.		2
382	Migraine as an inflammatory disorder with microglial activation as a prime candidate. <i>Neurological Research</i> , 2023, 45, 200-215.	0.6	13
383	An Up-to-Date Look at In Vitro Models of Nose-to-Brain Drug Delivery. , 2022, , 115-139.		0
384	Manual acupuncture benignly regulates blood-brain barrier disruption and reduces lipopolysaccharide loading and systemic inflammation, possibly by adjusting the gut microbiota. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	13
385	Cognitive Impairments and blood-brain Barrier Damage in a Mouse Model of Chronic Cerebral Hypoperfusion. <i>Neurochemical Research</i> , 0, , .	1.6	4
386	Altered gene expression in human brain microvascular endothelial cells in response to the infection of influenza H1N1 virus. <i>Animal Diseases</i> , 2022, 2, .	0.6	2
387	Walnut-derived peptides ameliorate d-galactose-induced memory impairments in a mouse model via inhibition of MMP-9-mediated blood-brain barrier disruption. <i>Food Research International</i> , 2022, 162, 112029.	2.9	6
388	OSI and Alzheimer's disease. , 2023, , 401-417.		0
389	Early-life stress affects peripheral, blood-brain barrier, and brain responses to immune challenge in juvenile and adult rats. <i>Brain, Behavior, and Immunity</i> , 2023, 108, 1-15.	2.0	5
390	Linking Cerebrovascular Dysfunction to Age-Related Hearing Loss and Alzheimer's Disease—Are Systemic Approaches for Diagnosis and Therapy Required?. <i>Biomolecules</i> , 2022, 12, 1717.	1.8	2
391	Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 43-70.	1.2	7
392	Is Periodontitis Associated with Age-Related Cognitive Impairment? The Systematic Review, Confounders Assessment and Meta-Analysis of Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15320.	1.8	6
393	Diabetic Retinopathy and Dementia Association, Beyond Diabetes Severity. <i>American Journal of Ophthalmology</i> , 2023, 249, 90-98.	1.7	3

#	ARTICLE	IF	CITATIONS
394	Vascular contributions to Alzheimer's disease. <i>Translational Research</i> , 2023, 254, 41-53.	2.2	26
395	Natural Product Co-Metabolism and the Microbiotaâ€“Gutâ€“Brain Axis in Age-Related Diseases. <i>Life</i> , 2023, 13, 41.	1.1	2
396	Analysis of Cerebral Small Vessel Changes in AD Model Mice. <i>Biomedicines</i> , 2023, 11, 50.	1.4	6
397	The neuroimmune axis of Alzheimerâ€™s disease. <i>Genome Medicine</i> , 2023, 15, .	3.6	59
398	Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. <i>Molecules</i> , 2023, 28, 1283.	1.7	5
399	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 229, 109478.	2.0	10
400	Physical activity for cognitive health promotion: An overview of the underlying neurobiological mechanisms. <i>Ageing Research Reviews</i> , 2023, 86, 101868.	5.0	22
401	Drug delivery to the brain â€“ lipid nanoparticles-based approach. <i>Pharmacia</i> , 2023, 70, 113-120.	0.4	5
402	Investigating the chemical profile of Rheum lhasaense and its main ingredient of piceatannol-3â€“O-Î²-D-glucopyranoside on ameliorating cognitive impairment. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114394.	2.5	0
403	Mechanistic and therapeutic role of <sc>NLRP3</sc> inflammasome in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 0, , .	2.1	8
404	Metabolic Syndrome as a Risk Factor for Alzheimerâ€™s Disease: A Focus on Insulin Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4354.	1.8	13
406	Disruptions of Circadian Rhythms and Sleep/Wake Cycles in Neurologic Disorders. <i>Healthy Ageing and Longevity</i> , 2023, , 461-480.	0.2	0
407	Antiretroviral drugs efavirenz, dolutegravir and bicitgravir dysregulate blood-brain barrier integrity and function. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
408	Brain iron acquisition: An overview of homeostatic regulation and disease dysregulation. <i>Journal of Neurochemistry</i> , 2023, 165, 625-642.	2.1	7
409	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimerâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7258.	1.8	7
412	Phytosome for Targeted Delivery of Natural Compounds: Improving Efficacy, Bioavailability, and Delivery across BBB for the Treatment of Alzheimer's Disease. <i>Frontiers in Clinical Drug Research CNS and Neurological Disorders</i> , 2023, , 262-282.	0.1	0
416	Neurobiological Mechanisms of Cognitive Decline Correlated with Brain Aging. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 127-146.	0.8	0
438	Cellular junction dynamics and Alzheimerâ€™s disease: a comprehensive review. <i>Molecular Biology Reports</i> , 2024, 51, .	1.0	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------